Nutra Pharma Announces New Telemarketing and Social Media Campaign Through MyNyloxin.com
April 03 2014 - 8:30AM
Marketwired
Nutra Pharma Announces New Telemarketing and Social Media Campaign
Through MyNyloxin.com
Nutra Pharma Is Announcing That MyNyloxin.com Is Beginning a
Social Media and Telemarketing Campaign for the distribution of the
Company's Over-The-Counter (OTC) Pain Reliever, Nyloxin(R)
CORAL SPRINGS, FL--(Marketwired - Apr 3, 2014) - Nutra Pharma
Corp. (OTCQB: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is announcing that MyNyloxin.com, a new company
that has the exclusive rights to market and distribute Nutra
Pharma's over-the-counter (OTC) pain reliever, Nyloxin®, in the
Network Marketing channel has signed an agreement that creates the
MyNyloxin Telemarketing Division (MTD). MTD will begin their
telemarketing campaign on April 7 to identify customers for
Nyloxin® as well as potential Distributors for MyNyloxin.com.
"The MyNyloxin Telemarketing Division will actively find
opportunity seekers to purchase and sell the Nyloxin Product line
which will also include Nyloxin Pet Pain Away," stated Dalton
Johnson, CEO of MyNyloxin.com. "They will begin with approximately
2,000 outbound calls daily with the goal of growing to over 70,000
daily calls by the end of 2014," he continued. "This is a proven
mechanism for rapid growth in our industry. Their marketers will
provide access to a superior pain relief product that customers
need as well as an innovative network marketing program which
offers a fair and balanced compensation plan for both the average
and ambitious MyNyloxin Independent Entrepreneur," he
concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic
pain. Nyloxin® is currently available in the United States as
an oral spray for treating back pain, neck aches, headaches, joint
pain, migraines, and neuralgia, and as a topical gel for treating
joint pain, neck pain, arthritis pain, and pain from repetitive
stress. In addition to its everyday strength formulation, Nyloxin®
is also offered in an extra strength formula for more advanced,
Stage 3, chronic pain. The Company will also make Pet Pain-Away
available by the end of the 2nd quarter. Pet Pain-Away is a new
product primarily aimed at treating moderate to severe chronic pain
in companion animals. It is specifically indicated to treat pain
from hip dysplasia, arthritis pain, joint pain, and general chronic
pain in companion animals. Specialized proteins in Pet Pain-Away
block the action of acetylcholine, a major stimulating
neurotransmitter in the nervous system and activator of the
inflammatory pathways. As a result, the pain and inflammation
pathways are temporarily shut off.
"MyNyloxin Distributors have been consistently increasing the
public awareness of Nyloxin," said Rik J Deitsch, Chairman and CEO
of Nutra Pharma Corporation. "This new campaign will begin with
over 2,000 calls daily to potential Nyloxin customers and potential
MyNyloxin Distributors. We believe that this may create significant
market penetration and subsequent sales growth over the next
several months," he concluded.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The launch of MTD should not be
construed as an indication in any way whatsoever of the future
value of the Company's common stock or its financial value. The
Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647
IR@nutrapharma.com
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Apr 2023 to Apr 2024